Transgene (TGNA) Financial Statements
Transgene Financial Overview
Transgene's market cap is currently $202.03M. The company's EPS TTM is $-0.17; its P/E ratio is -4.34; Transgene is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 490.00K | $ 6.35M | $ 7.90M | $ 3.13M | $ 9.99M |
| Gross Profit | $ 490.00K | $ -27.93M | $ -21.69M | $ -29.04M | $ -22.89M |
| Operating Income | $ -41.07M | $ -35.66M | $ -30.05M | $ -29.90M | $ -23.52M |
| EBITDA | $ -39.77M | $ -26.65M | $ -28.44M | $ -30.31M | $ -16.55M |
| Net Income | $ -37.52M | $ -33.97M | $ -22.33M | $ -32.81M | $ -20.00M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 111.86M | $ 16.67M | $ 15.67M | $ 26.83M | $ 49.57M |
| Total Assets | $ 138.83M | $ 42.17M | $ 45.22M | $ 66.44M | $ 101.84M |
| Total Debt | $ 2.06M | $ 10.40M | $ 1.35M | $ 2.45M | $ 3.84M |
| Net Debt | $ -4.60M | $ -6.44M | $ -14.32M | $ -1.95M | $ -2.07M |
| Total Liabilities | $ 17.09M | $ 26.97M | $ 29.61M | $ 28.59M | $ 34.63M |
| Stockholders' Equity | $ 121.73M | $ 15.20M | $ 15.61M | $ 37.84M | $ 67.21M |
| Cash Flow | |||||
| Free Cash Flow | $ -37.58M | $ -26.62M | $ -37.42M | $ -21.84M | $ -32.63M |
| Operating Cash Flow | $ -36.74M | $ -23.55M | $ -34.67M | $ -20.30M | $ -31.94M |
| Investing Cash Flow | $ -105.95M | $ -3.21M | $ 34.57M | $ 20.27M | $ 16.79M |
| Financing Cash Flow | $ 134.38M | $ 26.96M | $ 11.37M | $ -1.48M | $ 15.77M |
Currency in EUR